Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (211-220 of 477) with videos related to

Pageof 48
Sort By:
Arthritis and Rheumatism|February 1, 2006
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritisMichael H Weisman, Daniel E Furst, Grace S Park, et al.
Arthritis and Rheumatism|October 4, 2005
Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studiesDinesh Khanna, Grace S Park, Harold E Paulus, et al.
Arthritis Research & Therapy|June 24, 2009
The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort studyMatthew L Mundwiler, Paul Maranian, Douglas H Brown, et al.
ACR Open Rheumatology|May 21, 2020
Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study IIElizabeth R Volkmann, Donald P Tashkin, Holly LeClair, et al.
ACR Open Rheumatology|October 5, 2023
Economic and Health Care Resource Use Burden of Systemic SclerosisDinesh Khanna, Daniel E Furst, Justin W Li, et al.
Arthritis and Rheumatism|July 20, 2011
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseaseDinesh Khanna, Rajeev Saggar, Maureen D Mayes, et al.
Arthritis and Rheumatism|September 29, 2011
Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendationsLeslie R Harrold, J Timothy Harrington, Jeffrey R Curtis, et al.
Annals of the Rheumatic Diseases|October 25, 2018
Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levelsYukai Wang, Shaoqi Chen, Zhangzhang Lin, et al.
The Journal of Rheumatology|February 17, 2007
Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosisVanessa L Malcarne, Ingunn Hansdottir, Ann McKinney, et al.
Arthritis and Rheumatism|March 31, 2007
Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohortDinesh Khanna, MyungShin Oh, Daniel E Furst, et al.
Pageof 48

Showing results (211-220 of 477) with videos related to

Sort By:
Pageof 48
Arthritis and Rheumatism|February 1, 2006
Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritisMichael H Weisman, Daniel E Furst, Grace S Park, et al.
Arthritis and Rheumatism|October 4, 2005
Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studiesDinesh Khanna, Grace S Park, Harold E Paulus, et al.
Arthritis Research & Therapy|June 24, 2009
The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort studyMatthew L Mundwiler, Paul Maranian, Douglas H Brown, et al.
ACR Open Rheumatology|May 21, 2020
Treatment With Mycophenolate and Cyclophosphamide Leads to Clinically Meaningful Improvements in Patient-Reported Outcomes in Scleroderma Lung Disease: Results of Scleroderma Lung Study IIElizabeth R Volkmann, Donald P Tashkin, Holly LeClair, et al.
ACR Open Rheumatology|October 5, 2023
Economic and Health Care Resource Use Burden of Systemic SclerosisDinesh Khanna, Daniel E Furst, Justin W Li, et al.
Arthritis and Rheumatism|July 20, 2011
A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseaseDinesh Khanna, Rajeev Saggar, Maureen D Mayes, et al.
Arthritis and Rheumatism|September 29, 2011
Prescribing practices in a US cohort of rheumatoid arthritis patients before and after publication of the American College of Rheumatology treatment recommendationsLeslie R Harrold, J Timothy Harrington, Jeffrey R Curtis, et al.
Annals of the Rheumatic Diseases|October 25, 2018
Imaging and serum biomarkers in connective tissue disease-associated interstitial lung diseases: correlation between lung ultrasound B-lines and KL-6 levelsYukai Wang, Shaoqi Chen, Zhangzhang Lin, et al.
The Journal of Rheumatology|February 17, 2007
Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosisVanessa L Malcarne, Ingunn Hansdottir, Ann McKinney, et al.
Arthritis and Rheumatism|March 31, 2007
Evaluation of the preliminary definitions of minimal disease activity and remission in an early seropositive rheumatoid arthritis cohortDinesh Khanna, MyungShin Oh, Daniel E Furst, et al.
Pageof 48